ADIPOQ and type 2 diabetes mellitus: Interestingly, in an effort to find biomarkers capable of stratifying new-onset type 2 diabetes subjects into those with type 2 diabetes mellitus (T2DM) and those with PDAC-related diabetes, Oldfield L., et al. showed that the combination of adiponectin and interleukin-1 receptor antagonist (IL-1Ra) has strong diagnostic potential (AUC of 0.91; 95% CI: 0.84–0.99) for the distinction of PDAC-related diabetes from T2DM [75].